Truist Securities Reiterates Gilead Sciences (GILD) Buy Recommendation
Nasdaq Fintel reports that on September 6, 2023, Truist Securities reiterated coverage of Gilead Sciences (NASDAQ:GILD) with a Buy recommendation.
Analyst Price Forecast Suggests 25.54% Upside
As of August 30, 2023, the average one-year price target for Gilead Sciences is 93.20. The forecasts range from a low of 80.80 to a high of $121.80. The average price target represents an increase of 25.54% from its latest reported closing price of 74.24.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Gilead Sciences is 26,046MM, a decrease of 4.88%. The projected annual non-GAAP EPS is 6.89.
- For more in-depth coverage of Gilead Sciences, view the free, crowd-sourced company research report on Finpedia.
What is the Fund Sentiment?
There are 2870 funds or institutions reporting positions in Gilead Sciences. This is a decrease of 76 owner(s) or 2.58% in the last quarter. Average portfolio weight of all funds dedicated to GILD is 0.47%, a decrease of 7.97%. Total shares owned by institutions increased in the last three months by 0.93% to 1,249,941K shares. The put/call ratio of GILD is 0.87, indicating a bullish outlook.